{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:52:12Z","timestamp":1793958732306,"version":"4.8.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01451-9","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T03:15:15Z","timestamp":1771643715000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab"],"prefix":"10.1038","volume":"16","author":[{"given":"Febe","family":"Smits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaz","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte L. B. M.","family":"Korst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris A.","family":"Frerichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Kuipers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6836-055X","authenticated-orcid":false,"given":"Sandy","family":"Kruyswijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike E. M.","family":"de Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5666-5015","authenticated-orcid":false,"given":"Kazem","family":"Nasserinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"1451_CR1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"1451_CR2","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","volume":"29","author":"NJ Bahlis","year":"2023","unstructured":"Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29:2570\u20136.","journal-title":"Nat Med"},{"key":"1451_CR3","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"1451_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"1451_CR5","doi-asserted-by":"publisher","first-page":"TPS8069","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8069","volume":"40","author":"R Vij","year":"2022","unstructured":"Vij R, Schade H, Trudel S, Chang AC, Huang J, Samineni D, et al. CAMMA 1: a multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2022;40:TPS8069\u2013TPS8069.","journal-title":"J Clin Oncol"},{"key":"1451_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138:157.","journal-title":"Blood"},{"key":"1451_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","volume":"8","author":"KA Frerichs","year":"2024","unstructured":"Frerichs KA, Verkleij CPM, Mateos MV, Martin TG, Rodriguez C, Nooka A, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024;8:194\u2013206.","journal-title":"Blood Adv"},{"key":"1451_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31:383\u201395.","journal-title":"Cancer Cell"},{"key":"1451_CR9","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","volume":"130","author":"AK Nooka","year":"2024","unstructured":"Nooka AK, Rodriguez C, Mateos MV, Manier S, Chastain K, Banerjee A, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130:886\u2013900.","journal-title":"Cancer"},{"key":"1451_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711\u2013.e6.","journal-title":"Cancer Cell"},{"key":"1451_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615\u201328.","journal-title":"Blood"},{"key":"1451_CR12","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-cell characteristics impact response and resistance to T-cell\u2013redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30:3006\u201322.","journal-title":"Clin Cancer Res"},{"key":"1451_CR13","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"F Mazahreh","year":"2023","unstructured":"Mazahreh F, Mazahreh L, Schinke C, Thanendrarajan S, Zangari M, Shaughnessy JD Jr, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7:3069\u201374.","journal-title":"Blood Adv"},{"key":"1451_CR14","first-page":"421006","volume":"P942","author":"A Oriol","year":"2024","unstructured":"Oriol A, Popat R, Garfall A, Nooka A, Van de Donk NWCJ, Moreau P, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. EHA congress. 2024;P942:421006.","journal-title":"EHA congress"},{"key":"1451_CR15","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"AL Garfall","year":"2024","unstructured":"Garfall AL, Nooka AK, Van De Donk NWCJ, Moreau P, Bhutani M, Oriol A, et al. Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:7540\u20137540.","journal-title":"J Clin Oncol"},{"key":"1451_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"G Lancman","year":"2023","unstructured":"Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discov. 2023;4:440\u201351.","journal-title":"Blood Cancer Discov"},{"key":"1451_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"M Mohan","year":"2024","unstructured":"Mohan M, Monge J, Shah N, Luan D, Forsberg M, Bhatlapenumarthi V, et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 2024;14:35.","journal-title":"Blood Cancer J"},{"key":"1451_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.clml.2024.05.002","volume":"24","author":"T Lupia","year":"2024","unstructured":"Lupia T, Cani L, Bringhen S, Rosa FGD, Bruno B, Mikulska M, et al. Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians. Clin Lymphoma Myeloma Leuk. 2024;24:592\u2013603.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1451_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01282-0","volume":"15","author":"M Mohan","year":"2025","unstructured":"Mohan M, Szabo A, Cheruvalath H, Clennon A, Bhatlapenumarthi V, Patwari A, et al. Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma. Blood Cancer J. 2025;15:74.","journal-title":"Blood Cancer J"},{"key":"1451_CR20","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"Ludwig","year":"2023","unstructured":"Ludwig, Terpos H, Donk E, van de N, Mateos M-V, Moreau P, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24:e255\u2013e269.","journal-title":"Lancet Oncol"},{"key":"1451_CR21","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9:e143\u2013e161.","journal-title":"Lancet Haematol"},{"key":"1451_CR22","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","volume":"8","author":"H Ludwig","year":"2024","unstructured":"Ludwig H, Munshi NC, Terpos E, Schweitzer I, Raje N, Moreau P, et al. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma. Blood Adv. 2024;8:4979\u201382.","journal-title":"Blood Adv"},{"key":"1451_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/imr.12823","volume":"292","author":"C Fenwick","year":"2019","unstructured":"Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-cell exhaustion in HIV infection. Immunol Rev. 2019;292:149\u201363.","journal-title":"Immunol Rev"},{"key":"1451_CR24","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3389\/fimmu.2020.02153","volume":"11","author":"RE Cooke","year":"2020","unstructured":"Cooke RE, Quinn KM, Quach H, Harrison S, Prince HM, Koldej R, et al. Conventional treatment for multiple myeloma drives premature aging phenotypes and metabolic dysfunction in T cells. Front Immunol. 2020;11:2153.","journal-title":"Front Immunol"},{"key":"1451_CR25","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","volume":"6","author":"M Mohan","year":"2022","unstructured":"Mohan M, Nagavally S, Dhakal B, Radhakrishnan SV, Chhabra S, D\u2019Souza A, et al. Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Adv. 2022;6:2466\u201370.","journal-title":"Blood Adv"},{"key":"1451_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00808-8","volume":"13","author":"BZ Sim","year":"2023","unstructured":"Sim BZ, Longhitano A, Er J, Harrison SJ, Slavin MA, Teh BW. Infectious complications of bispecific antibody therapy in patients with multiple myeloma. Blood Cancer J. 2023;13:34.","journal-title":"Blood Cancer J"},{"key":"1451_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","volume":"30","author":"A Jourdes","year":"2024","unstructured":"Jourdes A, Cellerin E, Touzeau C, Harel S, Denis B, Escure G, et al. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study. Clin Microbiol Infect. 2024;30:764\u201371.","journal-title":"Clin Microbiol Infect"},{"key":"1451_CR28","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7:5898\u2013903.","journal-title":"Blood Adv"},{"key":"1451_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.132","volume":"8","author":"CLBM Korst","year":"2024","unstructured":"Korst CLBM, Groen K, Bosman PWC, van der Valk F, Verkleij CPM, Kruyswijk S, et al. Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: Implications for outpatient step-up dosing. HemaSphere. 2024;8:e132.","journal-title":"HemaSphere"},{"key":"1451_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/ITT.S31136","volume":"2","author":"S Jolles","year":"2013","unstructured":"Jolles S. Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. Immunol Targets Ther. 2013;2:125\u201333.","journal-title":"Immunol Targets Ther"},{"key":"1451_CR31","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.3390\/cancers15184524","volume":"15","author":"M Dimou","year":"2023","unstructured":"Dimou M, Speletas M, Milito C, Pyzik A, Huscher D, Kamieniak M, et al. Insights into facilitated subcutaneous immunoglobulin use in patients with secondary immunodeficiency diseases: a FIGARO subgroup analysis. Cancers. 2023;15:4524.","journal-title":"Cancers"},{"key":"1451_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.3390\/jcm14041203","volume":"14","author":"M Dimou","year":"2025","unstructured":"Dimou M, Vacca A, S\u00e1nchez-Ram\u00f3n S, Karakulska-Prystupiuk E, Lionikaite V, Siffel C, et al. Real-world effectiveness, safety, and tolerability of facilitated subcutaneous immunoglobulin 10% in secondary immunodeficiency disease: a systematic literature review. J Clin Med. 2025;14:1203.","journal-title":"J Clin Med"},{"key":"1451_CR33","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/path.1877","volume":"208","author":"JM Woof","year":"2006","unstructured":"Woof JM, Kerr MA. The function of immunoglobulin A in immunity. J Pathol. 2006;208:270\u201382.","journal-title":"J Pathol"},{"key":"1451_CR34","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022;140:1104\u201318.","journal-title":"Blood"},{"key":"1451_CR35","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1182\/blood-2023-189042","volume":"142","author":"F Eisele","year":"2023","unstructured":"Eisele F, Afrin N, Stanojkovska E, John M, Helal M, Grundheber L, et al. The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in myeloma patients treated with BCMA bispecific antibodies. Blood. 2023;142:1938.","journal-title":"Blood"},{"key":"1451_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2643-3230.BCD-24-0124","volume":"5","author":"NWCJ van de Donk","year":"2024","unstructured":"van de Donk NWCJ, Rasche L, Sidana S, Zweegman S, Garfall AL. T cell-redirecting bispecific antibodies in multiple myeloma: optimal dosing schedule and duration of treatment. Blood Cancer Discov. 2024;5:388\u201399.","journal-title":"Blood Cancer Discov"},{"key":"1451_CR37","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","volume":"20","author":"MT Drayson","year":"2019","unstructured":"Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2019;20:1760\u201372.","journal-title":"Lancet Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01451-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01451-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:02:15Z","timestamp":1772640135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01451-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1451"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01451-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KG has received payment\/honoraria for presentations from Bristol Myers Squibb and Beigene (no personal funding). KN is employed by CSL Behring as a contractor. SZ has received research funding from Takeda, Celgene, and Janssen. SZ participates in advisory boards of Takeda, Celgene, Janssen, Sanofi, Oncopeptides, and Amgen, all paid to the employer. NWCJvdD has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, Cellectis, and Bristol Myers Squibb. He serves on advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, Bristol Myers Squibb, Takeda, Roche, Novartis, Bayer, Pfizer, Merck, Kite Pharma, AbbVie, Adaptive, and Servier, all paid to the employer. All other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}